TITLE

Childhood cancer in Ireland: a population-based study

AUTHOR(S)
Stack, M.; Walsh, P. M.; Comber, H.; Ryan, C. A.; P. O.'Lorcain
PUB. DATE
October 2007
SOURCE
Archives of Disease in Childhood;Oct2007, Vol. 92 Issue 10, p890
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Population-based studies of childhood cancer incidence, survival and mortality make an important contribution to monitoring the successful implementation of new treatment guidelines and to understanding the epidemiology of these diseases. Methods: We analysed incidence and survival data for cancers diagnosed in children under 15 years of age in the Republic of Ireland during 1994–2000 (the first 7 years of National Cancer Registry coverage), and longer term mortality trends. Results: World age-standardised incidence rates in Ireland averaged 142 cases per million children per year, slightly higher than the European average and slightly lower than the US average, although differences varied by diagnostic group. Observed 5-year survival in Ireland (79% overall) was slightly higher than European and US averages, and was significantly higher for acute non-lymphocytic leukaemia (67%) and (compared with the USA) significantly lower for Hodgkin lymphoma (83%). No significant increases in incidence rates were evident from the available 7 years' data, either overall or for particular diagnostic groups. Rates of childhood cancer mortality have declined markedly since the 1950s. Conclusions: Data presented here are in line with other developed countries and suggest major improvements in treatment and consequent survival.
ACCESSION #
27151380

 

Related Articles

  • Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment. Brian L. Abbott // Oncologist;Jan2006, Vol. 11 Issue 1, p21 

    Chronic lymphocytic leukemia (CLL) is a low-grade B-lineage lymphoid malignancy but may have more heterogeneity than previously thought. Many cases require no treatment at all because of an indolent course, while other patients become symptomatic or develop signs of rapid progression. Treatment...

  • Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Abdulqadhr, Goran; Molin, Daniel; Å ström, Gunnar; Suurküla, Madis; Johansson, Lars; Hagberg, Hans; Ahlström, Håkan // Acta Radiologica;Mar2011, Vol. 52 Issue 2, p173 

    Background: Diffusion-weighted imaging (DWI) has become increasingly valuable in lymph node imaging, yet the clinical utility of this technique in the staging of lymphoma has not been established. Purpose: To compare whole-body DWI with FDG-PET/CT in the staging of lymphoma patients. Material...

  • Level of education and the risk of lymphoma in the European prospective investigation into cancer and nutrition. Hermann, Silke; Rohrmann, Sabine; Linseisen, Jakob; Nieters, Alexandra; Khan, Aneire; Gallo, Valentina; Overvad, Kim; Tjønneland, Anne; Raaschou-Nielsen, Ole; Bergmann, Manuela M.; Boeing, Heiner; Becker, Nikolaus; Kaaks, Rudolf; Bas Bueno-de-Mesquita, H.; May, Anne M.; Vermeulen, Roel C. H.; Bingham, Sheila; Khaw, Kay-Tee; Key, Timothy J.; Travis, Ruth C. // Journal of Cancer Research & Clinical Oncology;Jan2010, Vol. 136 Issue 1, p71 

    Lymphomas belong to the few cancer sites with increasing incidence over past decades, and only a few risk factors have been established. We explored the association between education and the incidence of lymphoma in the prospective EPIC study. Within 3,567,410 person-years of follow-up, 1,319...

  • Possible Imprinting and Microchimerism in Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders. Jønsson, Viggo; Tjønnfjord, Geir E.; Johannesen, Tom B.; Samuelsen, Sven Ove; Ly, Bernt // Translational Oncogenomics;2008, Issue 3, p15 

    Based on the concept that the tumorogenesis in chronic lymphocytic leukaemia comprises both an initial, inherited mutation and subsequent somatic mutations, the pleiotypic diversity of familial chronic lymphocytic leukaemia and related malignant lymphoproliferative disorders is generally...

  • On the origin of giant cells in Hodgkin lymphoma. Rengstl, Benjamin; Rieger, Michael A.; Newrzela, Sebastian // Communicative & Integrative Biology;Apr2014, Vol. 7, p1 

    The article discusses a study on the source of the giant tumor cells in Hodgkin's lymphoma. Topics discussed include how tumor cells are observed in lymphoid malignancies, how the refusion of Hodgkin cells leads to Reed-Sternberg (RS) formation, and how incomplete cytokinesis leads to Hodgkin...

  • Hodgkin's Disease and Autoimmune Hemolytic Anemia: A Case Report. GÜNEŞ, Fahri; AKBAL, Erdem; AKYÜREK, Ömer; CAN, Esra Sarıbacak; ALTINBAŞ, Mustafa // Ortadogu Medical Journal / Ortadogu Tip Dergisi;2013, Vol. 5 Issue 3, p163 

    Hodgkin's disease is a distinct monoclonal malignant disorder of the lymphatic system. Autoimmune hemolytic anemia, trombocytopenia and leukopenia can be present with lymphoproliferative disease especially chronic lymphocytic leukemia and Non-Hodgkin's lymphomas but they abnormalities rarely...

  • Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995–2002). Ascoli, V.; Minelli, G.; Kanieff, M.; Crialesi, R.; Frova, L.; Conti, S. // British Journal of Cancer;10/12/2009, Vol. 101 Issue 7, p1085 

    Background:Little information is available on the causes of death among persons with classic Kaposi's sarcoma (CKS).Methods:We conducted a population-based study in Italy to identify deceased persons with CKS and the underlying causes of death among them, by reviewing multiple-causes-of-death...

  • CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Prins, R C; Burke, R T; Tyner, J W; Druker, B J; Loriaux, M M; Spurgeon, S E // Leukemia (08876924);Oct2013, Vol. 27 Issue 10, p2094 

    A letter to the editor is presented in response to the article related to CX-4945, a selective inhibitor of casein kinase-2 (CK2) and enhanced activity in chronic lymphocytic leukemia in the August 27, 2013 issue.

  • The genomic landscape of chronic lymphocytic leukemia: clinical implications. Quesada, Víctor; Ramsay, Andrew J.; Rodríguez, David; Puente, Xose S.; Campo, Elías; López-Otín, Carlos // BMC Medicine;2013, Vol. 11 Issue 1, p1 

    A precise understanding of the genomic and epigenomic features of chronic lymphocytic leukemia (CLL) may benefit the study of the disease's staging and treatment. While recent reports have shed some light on these aspects, several challenges need to be addressed before translating this research...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics